Skip to main content
Contact Us
Subscribe
E-Edition
87°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Dyne Therapeutics Inc
(NQ:
DYN
)
42.83
-1.70 (-3.82%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Dyne Therapeutics Inc
< Previous
1
2
3
4
5
Next >
Why Is Rare Muscle Disease-Focused Dyne Therapeutics Stock Soaring Today?
January 03, 2024
Dyne Therapeutics Inc (NASDAQ: DYN) released initial clinical data from its ACHIEVE trial of DYNE-101 in patients with myotonic dystrophy type 1 (DM1) and its DELIVER trial of DYNE-251 in patients with...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 03, 2024
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 03, 2024
It's time to dive into the biggest pre-market stock movers with all of the latest coverage worth reading about on Wednesday morning!
Via
InvestorPlace
Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases
January 03, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Why Shares of Dyne Therapeutics Fell This Week
September 15, 2023
Insiders sold more than 15,000 shares of company stock on Tuesday.
Via
The Motley Fool
Dyne Therapeutics: Q1 Earnings Insights
May 11, 2023
Via
Benzinga
Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials
January 02, 2024
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
3 of the Best Cheap Stocks Under $20 to Buy Now: November Edition
November 13, 2023
After dropping to 52-week lows, the markets have been rallying, sending traders and investors are looking for cheap stocks under $20.
Via
InvestorPlace
Dyne Therapeutics to Present at November Investor Conferences
November 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones
October 30, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
What 4 Analyst Ratings Have To Say About Dyne Therapeutics
March 03, 2023
Via
Benzinga
Dyne Therapeutics to Present at October Investor Conferences
September 28, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
September 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Jefferies Healthcare Conference
June 01, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
May 25, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
May 17, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 11, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
May 03, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
May 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Acuity Brands, C3.ai And Other Big Stocks Moving Lower On Tuesday
April 04, 2023
U.S. stocks traded lower, with the Dow Jones dropping more than 100 points on Tuesday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
March 23, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
March 20, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics to Present at Upcoming Investor Conferences
March 07, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
March 02, 2023
From
Dyne Therapeutics, Inc.
Via
GlobeNewswire
Analyst Says This Small Cap Biotech Firm Has 'Very Valuable Therapeutic,' Upgrades Stock
February 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 27, 2023
February 27, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 15, 2023
February 15, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
February 07, 2023
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.